CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 181 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $125,425,669 | +3.1% | 3,388,967 | +16.9% | 9.68% | -24.0% |
Q1 2024 | $121,713,000 | +2.1% | 2,900,000 | -3.5% | 12.74% | -3.6% |
Q4 2023 | $119,214,153 | +35.4% | 3,005,904 | -6.1% | 13.21% | -8.3% |
Q3 2023 | $88,064,000 | -0.2% | 3,200,000 | +23.1% | 14.40% | +18.7% |
Q2 2023 | $88,218,000 | +74.0% | 2,600,000 | +84.5% | 12.13% | +85.3% |
Q1 2023 | $50,712,047 | -29.1% | 1,409,451 | -12.2% | 6.55% | -40.4% |
Q4 2022 | $71,552,232 | +59.1% | 1,605,390 | +0.3% | 10.98% | +15.8% |
Q3 2022 | $44,980,000 | +36.3% | 1,600,127 | +16.1% | 9.48% | +12.5% |
Q2 2022 | $33,002,000 | +28.7% | 1,378,659 | +83.1% | 8.43% | +1.3% |
Q1 2022 | $25,648,000 | +192.8% | 753,034 | +232.1% | 8.32% | +77.7% |
Q4 2021 | $8,761,000 | – | 226,726 | – | 4.68% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |